Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
-
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
-
Oregon Department of Transportation Selects Rekor Command® to Deliver Safety Alerts Directly to Drivers Statewide
-
MEXC Leads SOL and DOGE Market-Price Liquidity in CoinGecko's 2026 CEX Report
-
MEXC Leads SOL and DOGE Market-Price Liquidity in CoinGecko's 2026 CEX Report
-
Man Group PLC : Form 8.3 - Gamma Communications Plc
-
Form 8.5 (EPT/RI)-Pollen Street Group Limited
-
Man Group PLC : Form 8.3 - RHI Magnesita N.V.
-
Man Group PLC : Form 8.3 - Vesuvius Plc
-
Man Group PLC : Form 8.3 - Sthree plc
-
Share Purchase - Long Term Incentive Plans
-
Form 8.5 (EPT/RI)-Tribal Group Plc
-
Final result of S-Bank Plc’s voluntary recommended public cash tender offer for all the shares in Oma Savings Bank Plc: S-Bank Plc completes the tender offer and commences a subsequent offer period
-
Form 8.5 (EPT/RI)-SThree Plc
-
Link Publishers Heads to brightonSEO 2026 to Discuss the Future of Search Visibility
-
Ocugen to Participate in Upcoming Scientific Conferences
-
GDEV announces final results of previously announced self tender offer to purchase for cash up to $20,000,000 in value of its ordinary shares (or up to 1,813,236 Ordinary Shares) at a purchase price o
-
Vema Hydrogen Expands Canadian Team as Pilot Testing Advances, Appointing Quebec-based Stephane Dallaire as CFO
-
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
-
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
-
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
-
Classiq Introduces Fault Tolerance Engine to Bridge Quantum Applications and Fault-Tolerant Hardware
-
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
-
GlobalFoundries Announces Conference Call to Review Third Quarter 2026 Financial Results
-
Sono-Tek Announces Record $7.19 Million in Orders from Advanced Clean Energy Sector Customer
-
Argo Renews Bradford Smart Routing™ Agreement Through 2027
-
Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury
-
UNISYNC Announces Normal Course Issuer Bid and Automatic Securities Purchase Plan
-
ACM Research’s Operating Subsidiary ACM Research (Shanghai) Provides Backlog Data
-
Enigmatig Limited Issues Statement on Recent Share Trading Activity
-
GDEV announces final results of previously announced self tender offer to purchase for cash up to $20,000,000 in value of its ordinary shares (or up to 1,813,236 Ordinary Shares) at a purchase price
-
Ambow Launches HybriU Events On Demand, Bringing AI-Powered Hybrid Events to Venues in a Single Transport Case
-
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
-
Chilco River Holdings Advances Commercialization Across Premium Spirits Portfolio
-
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depres
-
Beamr Expects Fiscal Year 2026 Revenues to Increase by $1.5 Million Year Over Year
-
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
-
ONAR Completes Largest Acquisition in Company History: Advertise Purple Adds $17.1 Million of Revenue and $4.4 Million of Net Income, Bringing Combined Pro Forma Revenue to Approximately $23.5 Million
-
Northland Power Closes Financing for Two Battery Storage Projects in Poland
-
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
-
10 Barrel Expands Salty Sips RTD Portfolio with New Blackberry Refresher
-
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
-
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
-
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
-
FactSet Reports Results for Fourth Quarter and Fiscal 2026
-
GlobalFoundries Announces Conference Call to Review Third Quarter 2026 Financial Results
-
Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies
-
Chair of AB KN Energies Remuneration and Nomination Committee Elected
-
EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application
-
AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
